Policy of Using Development Pipeline Volume and Clinical Trial Progress as Important Management Indicators
First written in FY2022-Q3. 11 of 14 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 2 of 8 companies on the "Worse" side.
2 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「In the DTx product business, the company considers the number of medical institutions adopting the “サスメド insomnia disorder app Medcle®,” monthly prescription volume, the number of development pipeline programs ahead of financial indicators, and clinical trial progress to be important management indicators, with the aim of accelerating sales and maximizing revenue over the long term. In the DTx platform business, the number of contracts is considered an important management indicator for achieving sustained revenue growth.」
In addition to the number of development pipeline programs, clinical trial progress, and number of contracts used previously, the company designated the number of medical institutions adopting its products and monthly prescription volume as management indicators for measuring sales acceleration. - FY2026-H1RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2025-H1RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The company continues to pursue a policy of treating the number of development pipeline programs and clinical trial progress, which precede financial indicators, as key management indicators. - FY2024-Q3RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2024-Q2RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2024-Q1RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2023RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2023-Q3RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2023-Q2RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2023-Q1RestatedAnnual report
「To maximize revenue from a long-term perspective, we will continue to operate the business by treating the number of products in the development pipeline and clinical trial progress, which precede financial indicators, as important management indicators.」
The policy of treating the number of development pipeline products and clinical trial progress as important management indicators continues. - FY2022ReframedAnnual report
「In the DTx product business, the company treats the number of development pipeline programs and the clinical trial progress rate, which precede financial indicators, as key management indicators in order to maximize revenue from a long-term perspective. In the DTx platform business, it treats the number of contracts as a key management indicator in order to achieve sustained revenue growth.」
In addition to the number of development pipeline programs and clinical trial progress, the company explicitly identified the progress rate and the number of contracts in the platform business as indicators, broadening its organization of KPIs. - FY2022-Q3First statedAnnual report
「To maximize revenue from a long-term perspective, the company will continue to operate its business by treating the number of development pipeline programs and clinical trial progress, which precede financial indicators, as key management indicators.」
A policy was explicitly stated for the first time of treating the number of development pipeline programs and clinical trial progress, which precede financial indicators, as key management indicators.